| Agenda |
DAY
ONE - Tuesday 5 November 2002 |
|
Biotech in Europe |
| 08.50
|
Chairman:
Prof. Dr. Horst Domdey,
CEO,
Bio-M AG |
|
|
|
| 09.00
|
Introductory
Welcome
Dr. Christian Zschocke,
Managing Partner,
Morgan
Lewis & Bockius |
|
|
|
| 09.10
|
Re-Assessing
the Landscape of European Biotech
Hanns-Peter Wiese, Partner,
Global
Life Science Ventures |
|
|
|
| 09.30
|
The Future
of the Financing of Listed Biotech Companies
Robert Wyss, Head
of New Market,
SWX
Swiss Exchange |
|
Pharma R&D and
Collaboration |
| 09.50
|
External
R&D Collaborations in Big Pharma: An Option or a Must?
Dr. Romeo Paioni, Head
of Scientific and External Affairs,
Novartis
Pharma AG |
|
|
|
| 10.10
|
Dr
Ann Mills-Duggan, Director, Genetics & Discovery Ventures,
GlaxoSmithKline |
|
|
|
| 10.25
|
Finding
Financial and Strategic Support through Partnering in the Biotech
sector
Dr. Silvano Fumero,
Senior Executive Vice-President, Head of Research & Pharmaceutical
Development,
Serono
International S.A. |
|
|
|
| 10.40
|
BREAK |
|
Company Presentations:
Small-Cap and IPO Prospects |
| 11.00
|
|
| 11.20
|
| Antisoma
plc |
MWG-Biotech
AG |
|
| 11.40
|
|
|
Panel: Life Science
Investment Opportunities |
| 12.00
|
Chair:
Michael Lytton, General
Partner, Oxford
Bioscience Partners
• MPM
Capital – Dr.
Michael Steinmetz, General Partner
• Atlas
Venture – Rob
Zegelaar, Senior Principal
• Merlin
Biosciences – Mark
Clement, Managing Director of European Operations
• Techno
Venture Management - Dr.
Hubert Birner, Partner |
|
|
|
| 13.00
|
LUNCH |
| 14.15-16.45 |
30 Start-Up to Pre-IPO
Company Presentations |
|
|
Bioinformatics, SNP,
Array Technology |
Post-Genomics:
Pharmacogenomics
& Proteomics |
Therapeutics:
Chaired by
Dr. Kai-Uwe Bindseil
BioTop
|
Immunology/
Oncology |
|
|
|
|
| 16.50
|
BREAK |
|
|
|
| 17.05
|
|
|
|
|
| 18.15
|
COCKTAIL
PARTY |
| Agenda |
DAY
TWO - Wednesday 6 November 2002 |
| 08.50
|
Chairman's
Introduction:
Peter
Kuchenbuch, Life Science Correspondent,
Financial
Times Deutschland |
|
|
|
| 09.00
|
U.S. Keynote
Perspectives of a U.S. Venture Capitalist Investing in European
Biotech Companies: Differing Investment Considerations on Each Side
of the Atlantic
Oxford
Bioscience Partners - Michael
Lytton, General Partner |
|
|
|
| 09.20
|
Godelieve
Quisthoudt-Rowohl
Member of the european Parliament
Quaestor |
|
|
|
09.35
-
10.20 |
Panel:
Global Development of Biotechnology Markets
With Representation from:
• German
Association of Biotechnology Industries (DIB)
Dr. Jens A. Katzek,
Managing Director
• BankInvest
Bio Venture
Prof. Dr. Jesper Zeuthen,
Managing Director
• NMT
Management AG
Andre Lamotte, Founder,
Investment Manager
• Earlybird
Venture Capital GmbH & Co KG
Dr. Marion Doerner,
Principal |
|
|
|
| 10.20
|
BREAK |
| 10.30-12.30 |
20 Streamed Start-Up
to Pre-IPO Company Presentations |
|
|
| Immunology/Oncology |
Therapeutics |
| Drug Delivery |
|
|
|
|
|
|
|
|
|
| 13.30
|
NETWORKING
LUNCH |
|
|
|
| 15.00
|
Close
of Conference
Back to top
|